Pfizer and BioNTech Announce Early Positive Update from German Phase 1/2 COVID-19 Vaccine Study, Including First T Cell Response Data

NEXT STORY
Vaxil Provides Pre-Clinical and Business Update
PREV STORY
Enlivex Announces a new publication “Apoptotic cell therapy for cytokine storm associated with acute severe sepsis” in Cell Death & Disease, a Nature Research Journal
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

RedHill Biopharma Enrolls 400th Patient in Confirmatory Phase III Study with TALICIA® for H. pylori Infection

400 of the planned total of 444 patients have been enrolled in the ongoing ...

author_avatar
NASDAQ Market News

NANOBIOTIX Strengthens U.S. leadership with appointments of Head of U.S. Clinical Development and Director of Investor Relations

PARIS and CAMBRIDGE, Mass., Oct. 3, 2016 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - ...

author_avatar
NASDAQ Market News

Crown Bioscience Inc. Announcing the 2017 Board of Directors Election Results

TAIPEI, Taiwan, Nov. 09, 2017 (GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary of ...

author_avatar
NASDAQ Market News